X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

With Discovery, Skullcap A Perfect Fit For Modern Medicine

Content Team by Content Team
28th January 2023
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

A collaboration between Chinese researchers and UK researchers has led to the unlocking of facilities related to evolutionary secrets that help the medicinal herb called barbed skullcap develop cancer-fighting compounds.

The CEPAMS partnership made use of DNA sequencing tech to put in place the genomic sequence of the skullcap, also known as a banzhilian in China.

All this gave researchers genetic information, a history related to microevolution, which are required to pinpoint how the plant builds the compound scutebarbatine A, which is useful in fighting a range of cancer cells.

Group Leader, Professor Cathie Martin of the John Innes Center, and other authors of the research stated that they have found that a primary metabolite has activity against cancer cells but not against non-cancer cells, which is notably important in the case of an anti-cancer metabolite. They are currently looking to introduce synthetic methods in order to produce more lead compounds.To isolate medicinal chemistry from the plant, in traditional Chinese medicine, the herb gets boiled in water for almost 2 hours, and then the extract is dried to develop a powder, which is then taken as a decoction. With the knowledge of the genes that make for the biochemical pathway in the anti-cancer activity related to herb, scientists are almost their to be able to synthesize compounds of larger sizes in a quicker way and that too sustainably through using yeast as a host.

The research that happens to be a part of Molecular Plant in the journal is carried by CEPAMS which is a collaboration between Chinese academy of science and John Innes Centre. As per professor Martin, this happens to be a great collaboration that develops worthy drug leads that too from natural resources and puts forth the value of aiming on species’ microevolution.

For treatment of varied medical conditions, the skullcap genus has been used for centuries in TCM. Preparations that are based on Scutellaria barbata at the time of chemotherapy have shown that the risk of metastatic tumours can be reduced.

Dr. Evangelos Tatsis, CEPMAS group leader who is based at Shanghai, natural products for ages have been the lead compounds for new drug discovery. By following the track of the traditional Chinese plants, novel anti-cancer medicines can be developed, and this research is indeed a crucial step in this regard.

Leads for the new drug discovery have often been provided by plant-based traditional medicines. It is well to be noted that taxol and vinblastine are clinically used as drugs against anticancer. TCM happens to be one of the best documented systems with information on the therapeutic herbal remedies’ properties.

Previous Post

New Algorithms That Lead To Personalized Cancer Treatments

Next Post

A New UK Manufacturing Regulatory Framework On The Cards

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
A New UK Manufacturing Regulatory Framework On The Cards

A New UK Manufacturing Regulatory Framework On The Cards

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In